Karo Intressenter AB increases the offer price in its public cash offer to the shareholders in Karo Pharma Aktiebolag and extends the acceptance period
On 29 October 2018, EQT VIII[1] (“EQT VIII”), through Karo Intressenter AB[2] (“Karo Intressenter”), announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (”Karo Pharma”) to acquire all outstanding shares[3] in Karo Pharma (the ”Offer”). Karo Intressenter has decided to increase the price in the Offer from SEK 36.90 in cash per share to SEK 38.00 in cash per share. Karo Intressenter further extends the acceptance period up to and including 17:00 (CET) on 17